Abstract
Importance

20
Considering colorectal cancer is the third leading cancer-related cause of death within the United 21 States, it is important to detect colorectal tumors early and to prevent the formation of tumors. 22 Short-chain fatty acids (SCFAs) are often used as a surrogate for measuring gut health and for 23 being anti-carcinogenic because of their anti-inflammatory properties. We evaluated the fecal SCFA 24 concentration of a cohort of individuals with varying colonic tumor burden who were previously 25 analyzed to identify microbiome-based biomarkers of tumors. We were unable to find an association 26 between SCFA concentration and tumor burden or use SCFAs to improve our microbiome-based 27 models of classifying people based on their tumor status. Furthermore, we were unable to find an 28 association between the fecal community structure and SCFA concentrations. Our results indicate 29 that the association between fecal SCFAs, the gut microbiome, and tumor burden is weak. 30 may confer beneficial effects against colorectal cancer. Regardless, there is a lack of consistent 48 evidence that increasing SCFA concentrations can protect against colorectal cancer in humans. 49 Case-control studies that have investigated possible associations between SCFAs and colon tumor 50 status have been plagued by relatively small numbers of subjects, but have reported increased total 51 and relative fecal acetate levels and decreased relative fecal butyrate concentrations in subjects with 52 colonic lesions (13). In randomized controlled trials fiber supplementation has been inconsistently 53 associated with protection against tumor formation and recurrence (14, 15) . Such studies are 54 confounded by difficulties ensuring subjects took the proper dose and using subjects with prior 55 polyp history who may be beyond a point of benefiting from fiber supplementation. Together, these 56 findings temper enthusiasm for treatments that target the production of SCFAs or for using them as 57 biomarkers for protection against tumorigenesis.
58
Fecal SCFA concentrations did not vary with diagnosis or treatment. To test for a significant 59 association between colorectal cancer and SCFAs, we quantified the concentration of acetate, 60 propionate, and butyrate in feces of previously characterized individuals with normal colons (N=172) 61 and those with colonic adenomas (N=198) or carcinomas (N=120) (16). We were unable to detect 62 a significant difference in any SCFA concentration across the diagnoses groups (all P>0.15; Figure   63 1A). Among the individuals with adenomas and carcinomas, a subset (N adenoma =41, N carcinoma =26) 64 were treated and sampled a year later (17). None of the individuals showed signs of recurrence 65 and yet none of the SCFAs exhibited a significant change with treatment (all P>0.058; Figure 1B ).
66
For both the pre-treatment cross-sectional data and the pre/post treatment data, we also failed to 67 detect any significant differences in the relative concentrations of any SCFAs (P>0.16). Finally, we 68 pooled the SCFA concentrations on a total and per molecule of carbon basis and again failed to 69 observe any significant differences (P>0.077). Although some of the P-values from our analyses 70 were close to 0.05, the effect sizes were all relatively small and inconsistent given the disease 71 progression ( Figure 1 ). These results demonstrated that there were no significant associations 72 between fecal SCFA concentration and diagnosis or treatment.
73
Combining SCFA and microbiome data does not improve the ability to diagnose individual 74 as having adenomas or carcinomas using a random forest model. We previously found that Figure 2A ). These data demonstrate that knowledge of the SCFA profile from a subject's fecal 87 sample did not improve the ability to diagnose a colonic lesion.
88
Knowledge of microbial community structure does not predict SCFA concentrations using 89 a random forest model. We next asked whether the fecal community structure was predictive 90 of fecal SCFA concentrations, regardless of a person's diagnosis. We trained random forest 91 regression models using 16S rRNA gene sequence data binned into OTUs and genera to predict the 92 concentration of the SCFAs ( Figure S2 ). The largest R 2 between the observed SCFA concentrations 93 and the modeled concentrations was 0.14, which was observed when using genus data to predict 94 butyrate concentrations ( Figure 2B ). We also used a smaller dataset of shotgun metagenomic 95 sequencing data generated from a subset of our cohort (N normal =27, N adenoma =25, and N cancer =26) 96 (18). We binned genes extracted from the assembled metagenomes into operational protein families 97 (OPFs) or KEGG categories and trained random forest regression models using metagenomic 98 sequence data to predict the concentration of the SCFAs ( Figure S2 ). Similar to the analysis using 99 16S rRNA gene sequence data, the metagenomic data was not predictive of SCFA concentration.
100
The largest R 2 was 0.055, which was observed when using KEGG data to predict propionate 101 concentrations ( Figure 2B ). Because of the limited number of samples that we were able to 102 generate metagenomic sequence data from, we used our 16S rRNA gene sequence data to impute 103 metagenomes that were binned into metabolic pathways or KEGG categories using PICRUSt Sequence Read Archive (study SRP108915). Fecal DNA was subjected to shotgun sequencing on 159 an Illumina HiSeq using 125 bp paired end reads. The archived sequences were already quality 160 filtered and aligned to the human genome to remove contaminating sequence data. We downloaded 161 the sequences and assembled them into contigs using MEGAHIT (22), which were used to identify 162 open reading frames (ORFs) using Prodigal (23). We determined the abundance of each ORF 163 by mapping the raw reads back to the ORFs using Diamond (24). We clustered the ORFs into 164 operational protein families (OPFs) in which the clustered ORFs were more than 40% identical to 165 each other using mmseq2 (25). We also used mmseq2 to map the ORFs to the KEGG database 166 and clustered the ORFs according to which category the ORFs mapped. Six values of mtry were tested and the value that provided 180 the largest AUROC or R 2 was selected. We trained the random forest model using the selected 181 mtry value and predicted the held-out test set. The data-split, hyperparameter selection, training 182 and testing steps were repeated 100 times to get a reliable and robust reading of model prediction 183 performance. We used AUROC and R 2 as the prediction performance metric for classification 184 and regression models, respectively. We used the randomForest R package (version 4.6-14) as 185 implemented in the caret R package (version 6.0-81) for developing and testing our models. for the held out data for the model generated using only the SCFAs, we compared the distribution of 194 the data to the expected median of 0.5 using the Wilcoxon rank sum test to test whether the model 195 performed better than would be achieved by randomly assigning the data to each diagnosis. When 196 we compared the random forest models generated without and with SCFA data included, we used 197 Wilcoxon rank sum tests to determine whether the models with the SCFA data included did better. to predict the concentration of each SCFA using each individuals' microbiome data generated 303 using 16S rRNA gene sequence and metagenomic sequence data. These regression models were 304 generated by partitioning the samples into a training set with 80% of the data and a testing set with 305 the remaining samples for 100 randomizations. 
